Shunqiang Li

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-49875-w, published online 03 July 2024 In the version of this article initially published, the palbociclib image in Fig. 2k was an inadvertent duplicate of the palbociclib image in Fig. 2j. Source data containing the original, uncropped images used to generate the figure are available (https://doi.org/10.6084/m9.figshare.31356262). The figure has been updated in the HTML and PDF versions of the article.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Abstract HER2 (ERBB2) is a major therapeutic drug target in breast cancer and The Cancer Genome Atlas (TCGA) Breast Cancer project and other studies have identified HER2 activating mutations in breast cancers without HER2 gene amplification. HER2 activating mutations occur in 2-5% of metastatic breast cancer patients (MBC), and clinical trials have shown that the irreversible pan-HER tyrosine kinase inhibitor, neratinib, produces a 31-40% clinical benefit rate for HER2 mutated MBC patients.